AR062154A1 - Derivados de pirazoles como inhibidores p450 (cyp450) - Google Patents

Derivados de pirazoles como inhibidores p450 (cyp450)

Info

Publication number
AR062154A1
AR062154A1 ARP070102977A ARP070102977A AR062154A1 AR 062154 A1 AR062154 A1 AR 062154A1 AR P070102977 A ARP070102977 A AR P070102977A AR P070102977 A ARP070102977 A AR P070102977A AR 062154 A1 AR062154 A1 AR 062154A1
Authority
AR
Argentina
Prior art keywords
cr9r10
cycloalkyl
alkyl
groups
independently selected
Prior art date
Application number
ARP070102977A
Other languages
English (en)
Inventor
Rongliang Chen
Simon Paul Planken
Scott Channing Sutton
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR062154A1 publication Critical patent/AR062154A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicacion 1: Un compuestos de formula (1), en la que, R1 es alquilo C1-8, -(CR9R10)tR11, -(CR9R10)tC(O)R11, -(CR9R10)tC(O)N(R13R14), -(CR9R10)t-(heterociclil de 3-10 miembros)-R11 o -(CR9R10)t(heteroaril de 5-9 miembros)-R11; R2 es heteroarilo de 5-9 miembros, opcionalmente sustituido con uno o más grupos R11; R3, R4, R5, R6, R7 y R8 se selecciona cada uno de forma independiente de hidrogeno, halogeno, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, -(CR9R10)t(cicloalquilo C3-8), - (CR9R10)tOR11-, -(CR8R10)tN(R11R12), -CN, -NO2, -CF3, -C(O)R9 y -C(O)2R9; cada R9 y R10 se selecciona de forma independiente de hidrogeno, alquilo C1-8, cicloalquilo C3-8, arilo C6-10, heterociclilo de 3-10 miembros y heteroarilo de 5-9 miembros; cada R11 y R12 se selecciona de forma independiente de hidrogeno, alquilo C1-8, cicloalquilo C3-8, arilo C6-10, heterociclilo de 3-10 miembros, heteroarilo de 5-9 miembros, -CN, halogeno, -(CR16R17)tOR18, y -(CR16R17)tC(O)R18, en los que cada uno de dichos grupos alquilo C1-8, cicloalquilo C3-8, arilo C6-10, heterociclilo de 3-10 miembros y heteroarilo de 5-9 miembros, está opcionalmente sustituido con uno o más grupos R15; R13 y R14 se seleccionan de forma independiente de hidrogeno, alquilo C1-8 y cicloalquilo C3-8, en los que dichos grupos alquilo C1-8 y cicloalquilo C3-8 están opcionalmente sustituidos con uno o más grupos R15; o R13 y R14, junto con el átomo de nitrogeno al que están unidos forman un grupo heterociclilo de 3-10 miembros, opcionalmente sustituido con uno o más grupos R15; cada R15 se selecciona de forma independiente de -(CR9R10)tR16, -(CR9R10)t(heterocicliIo de 3-10 miembros), -(CR9R10)t(cicloalquilo C3-8), -(CR9R10)t(heteroarilo de 5-9 miembros), - (CR9R10)t(arilo C6-10), -(CR9R10)tN(R16R17), -(CR9R10)tNR16C(O)R17, -(CR9R10)tOR16, -(CR9R10)tC(O)R16, -(CR9R10)tC(O)2R16, -(CR9R10)tC(O)N(R16R17), -(CR9R10)tNR16C(O)OR17, -(CR9R10)tNR16S(O)N(R17R18), -(CR9R10)tNR16S(O)2N(R17R18), - (CR9R10)tNR16S(O)R17, -(CR9R10)tNR16S(O)2R17, -(CR9R10)tNR16C(O)N(R17R18), -(CR9R10)t(halogeno), -(CR9R10)tOR16 y -(CR9R10)tS(O)2R16, en los que cada uno de dichos grupos heterociclilo de 3-10 miembros, cicloalquilo C3-8, heteroarilo de 5-9 miembros y arilo C6-10 está opcionalmente sustituido con uno o más grupos R16; cada R16, R17, y R18 se selecciona de forma independiente de hidrogeno, alquilo C1-8, -(CH2)t(cicloalquilo C3-8), -(CH2)t(arilo C6-10), -(CH2)t(heteroarilo de 5-9 miembros), - (CH2)t(heterociclilo de 3-10 miembros), halogeno, -OCH3 y -OH; R19 y R20 se seleccionan de forma independiente de hidrogeno y alquilo C1-8; y cada t se selecciona de forma independiente de 0, 1, 2, 3 y 4; o una sal o solvato del mismo farmacéuticamente aceptable.
ARP070102977A 2006-07-05 2007-07-03 Derivados de pirazoles como inhibidores p450 (cyp450) AR062154A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80659606P 2006-07-05 2006-07-05
US91098807P 2007-04-10 2007-04-10
US94180807P 2007-06-04 2007-06-04

Publications (1)

Publication Number Publication Date
AR062154A1 true AR062154A1 (es) 2008-10-22

Family

ID=38515807

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102977A AR062154A1 (es) 2006-07-05 2007-07-03 Derivados de pirazoles como inhibidores p450 (cyp450)

Country Status (24)

Country Link
US (1) US7919488B2 (es)
EP (1) EP2046774A1 (es)
KR (1) KR20090034958A (es)
CN (1) CN101511812A (es)
AP (1) AP2009004763A0 (es)
AR (1) AR062154A1 (es)
AU (1) AU2007270814B2 (es)
CA (1) CA2660031A1 (es)
CO (1) CO6150178A2 (es)
CR (1) CR10573A (es)
EA (1) EA200900135A1 (es)
GT (1) GT200700053A (es)
IL (1) IL196490A0 (es)
MA (1) MA30629B1 (es)
MX (1) MX2009000482A (es)
NO (1) NO20090346L (es)
NZ (1) NZ574207A (es)
PE (1) PE20080998A1 (es)
RS (1) RS20090036A (es)
TN (1) TN2009000033A1 (es)
TW (1) TWI334867B (es)
UY (1) UY30460A1 (es)
WO (1) WO2008004096A1 (es)
ZA (1) ZA200900478B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101534824A (zh) * 2006-11-17 2009-09-16 艾博特公司 作为化学活素受体拮抗剂的氨基吡咯烷
CA2680360A1 (en) * 2007-03-13 2008-09-18 Arete Therapeutics, Inc. 4-piperidinylurea compounds as soluble epoxide hydrolase inhibitors
JP2011512359A (ja) 2008-02-14 2011-04-21 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のアンタゴニストとしての環式ジアリールエーテル化合物
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
DE102008057343A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041242A1 (de) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057344A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041241A1 (de) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 Substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057364A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Substituierte Aryl-Verbindungen und ihre Verwendung
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
MX2012015252A (es) 2010-06-30 2013-05-30 Ironwood Pharmaceuticals Inc Estimuladores de sgc.
CN107266433A (zh) 2010-11-09 2017-10-20 铁木医药有限公司 sGC刺激剂
CN104066731B (zh) 2011-12-27 2016-06-15 铁木医药有限公司 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类
WO2014000178A1 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug
CN104540813A (zh) * 2012-06-27 2015-04-22 默沙东公司 磺酰胺衍生物以及使用它们用于改善药物的药物动力学的方法
WO2014194519A1 (en) * 2013-06-07 2014-12-11 Merck Sharp & Dohme Corp. Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug
WO2015070367A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Piperidine or piperazine linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
WO2015070366A1 (en) * 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
WO2020163689A1 (en) * 2019-02-08 2020-08-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education 20-hete formation inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0024795D0 (en) 2000-10-10 2000-11-22 Hoffmann La Roche Pyrazole derivatives for the treatment of viral diseases
DE60201740T2 (de) * 2001-04-05 2005-11-03 Torrent Pharmaceuticals Ltd., Ahmedabad Heterocyclische verbindungen für alterungs und diabetes bedingte vasculare erkrankungen
US7008953B2 (en) * 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7662844B2 (en) * 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
EA014329B1 (ru) 2005-09-23 2010-10-29 Пфайзер Продактс Инк. Пиридинаминосульфонилзамещенные бензамиды в качестве ингибиторов цитохрома р450 3а4 (cyp3a4)

Also Published As

Publication number Publication date
US7919488B2 (en) 2011-04-05
UY30460A1 (es) 2008-02-29
AU2007270814A1 (en) 2008-01-10
TW200811159A (en) 2008-03-01
WO2008004096A1 (en) 2008-01-10
CO6150178A2 (es) 2010-04-20
CN101511812A (zh) 2009-08-19
AP2009004763A0 (en) 2009-02-28
NZ574207A (en) 2010-10-29
NO20090346L (no) 2009-02-19
EP2046774A1 (en) 2009-04-15
RS20090036A (en) 2010-06-30
TN2009000033A1 (fr) 2010-08-19
GT200700053A (es) 2009-08-03
MA30629B1 (fr) 2009-08-03
CA2660031A1 (en) 2008-01-10
ZA200900478B (en) 2010-04-28
MX2009000482A (es) 2009-01-27
TWI334867B (en) 2010-12-21
IL196490A0 (en) 2011-07-31
PE20080998A1 (es) 2008-08-15
AU2007270814B2 (en) 2011-07-14
CR10573A (es) 2009-02-12
KR20090034958A (ko) 2009-04-08
US20080021011A1 (en) 2008-01-24
EA200900135A1 (ru) 2009-06-30

Similar Documents

Publication Publication Date Title
AR062154A1 (es) Derivados de pirazoles como inhibidores p450 (cyp450)
AR061486A1 (es) Derivados de 2-pirazinacarboxamida
ES2515095T3 (es) Derivados de adamantil acetamida como inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo 1
ES2647664T3 (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (AMD)
AR050364A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en terapeutica
AR069796A1 (es) Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen
CO6150164A2 (es) Derivados de 2-metilmorfolina pirido-,pirazo-ypirimido-pirimidina como inhibidores de mtor
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR064155A1 (es) Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
CO6261379A2 (es) Compuestos de ciclopentandiona y derivados utiles como herbicidas
AR084849A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
AR062900A1 (es) Derivados de isoquinolina y de quinazolina utiles como inhibidores de quinasa rho
AR056445A1 (es) Derivados arilicos y heteroarilicos de 6 miembros para tratar virus
CO6251352A2 (es) Derivados de ciclopentanodiona activos como herbicidas
AR070648A1 (es) Derivados de bencimidazol sustituido
AR078168A1 (es) Derivados de piperidinas y piperazinas, procesos para prepararlos y sus usos como moduladores de gpr119
AR065811A1 (es) Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos.
AR079199A1 (es) Composiciones farmaceuticas que comprenden ligandos de receptores sigma
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
ECSP088479A (es) Derivados de oxadiazol
AR060903A1 (es) Derivados de 1,2,3,4-tetrahidro-quinolina como inhibidores de cetp
CO2020001326A2 (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
RU2010123895A (ru) Гетероциклические соединения

Legal Events

Date Code Title Description
FA Abandonment or withdrawal